Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-1

Eli Lilly · Phase 3 · Completed · Enrollment 2539

NCT04184622

ArmPopulationDoseWeeksEstimandWeight change
PlaceboObesity, no T2Dn/r72ITT-3.1% at week 72
5 mg TirzepatideObesity, no T2D5 mg72ITT-15% at week 72
10 mg TirzepatideObesity, no T2D10 mg72ITT-19.5% at week 72
15 mg TirzepatideObesity, no T2D15 mg72ITT-20.9% at week 72